{"id":881,"date":"2026-04-11T02:42:46","date_gmt":"2026-04-11T02:42:46","guid":{"rendered":"https:\/\/www.europesays.com\/spain\/881\/"},"modified":"2026-04-11T02:42:46","modified_gmt":"2026-04-11T02:42:46","slug":"michel-sadelain-awarded-bbva-foundation-frontiers-of-knowledge-prize-for-revolutionizing-cancer-treatment-with-cell-therapies","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/spain\/881\/","title":{"rendered":"Michel Sadelain Awarded BBVA Foundation Frontiers of Knowledge Prize for Revolutionizing Cancer Treatment with Cell Therapies"},"content":{"rendered":"<p>Michel Sadelain, director of the <a href=\"https:\/\/www.vagelos.columbia.edu\/departments-centers\/columbia-initiative-cell-engineering-and-therapy\" rel=\"nofollow noopener\" target=\"_blank\">Columbia Initiative in Cell Engineering and Therapy<\/a> (CICET), has been awarded a <a href=\"https:\/\/www.frontiersofknowledgeawards-fbbva.es\/noticias\/18th-edition-frontiers-of-knowledge-award-biology-biomedicine-carl-june-michel-sadelain\/\" rel=\"nofollow noopener\" target=\"_blank\">BBVA Foundation Frontiers of Knowledge Prize in Biology and Biomedicine<\/a> for revolutionizing cancer treatment with CAR-T cell therapy, which modifies a patient\u2019s own T cells to seek and destroy cancer cells.<\/p>\n<p>The award, shared with Carl June of the University of Pennsylvania, recognizes the researchers\u2019 roles in pioneering techniques to isolate T cells from a patient\u2019s immune system and outfit the cells with synthetic receptors to enable them to recognize and kill cancer cells when infused back into the patient\u2019s body.<\/p>\n<p>First envisioned in the early 1990s, chimeric antibody receptor T-cell therapies targeting CD19, a protein expressed in leukemias and lymphomas, showed early promise in laboratory and preclinical studies conducted by both researchers. <\/p>\n<p>In 2017, the FDA approved the first CAR-T therapy for the treatment of patients with B cell acute lymphoblastic leukemia whose cancer had progressed after treatment with chemotherapy. Since then, seven CAR-T therapies have been approved by the FDA and used to treat over 50,000 patients with blood cancers such as leukemia, lymphomas, and myelomas, leading to remission for many.<\/p>\n<p>\u201cIt is now widely accepted that engineered immunity exemplified by CAR-T cells can succeed where no other treatment, chemotherapy, or bone marrow transplantation has\u00a0 before,\u201d Sadelain says.<\/p>\n<p>Currently, Sadelain and others at CICET are working to adapt CAR-T cell therapy for the treatment of a variety of solid tumors, infectious diseases, and autoimmune disorders. \u00a0<\/p>\n<p>\u201cI believe there\u2019s every reason to be optimistic that in the next few years, certainly the next decade, we will have effective CAR-T cell therapies for brain tumors and other solid cancers,\u201d Sadelain says. \u201cAnd recently, we have seen remarkable responses to CAR-T therapies in patients with autoimmune diseases such as lupus.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Michel Sadelain, director of the Columbia Initiative in Cell Engineering and Therapy (CICET), has been awarded a BBVA&hellip;\n","protected":false},"author":2,"featured_media":882,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[123],"tags":[148],"class_list":{"0":"post-881","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-bbva","8":"tag-bbva"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/spain\/wp-json\/wp\/v2\/posts\/881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/spain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/spain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/spain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/spain\/wp-json\/wp\/v2\/comments?post=881"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/spain\/wp-json\/wp\/v2\/posts\/881\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/spain\/wp-json\/wp\/v2\/media\/882"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/spain\/wp-json\/wp\/v2\/media?parent=881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/spain\/wp-json\/wp\/v2\/categories?post=881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/spain\/wp-json\/wp\/v2\/tags?post=881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}